Company: VMCWF
Filing Date: 2025-03-31
Form Type: 10-K
Source: 0001641172-25-001827
Chunk: 684

Company: Valuence Merger Corp. I
Filing Date: 2025-03-31
Form: 10-K
Item: Item 5
Chunk 684
---
SPAC transactions. Prior to Nomura Greentech, Mr. Hyung was at Deutsche Bank, where he focused on origination
and execution of M&A, debt and equity financing across the technology, media, and telecommunications sectors. Mr. Hyung received
his B.A. from University of Toronto and M.B.A. from Cornell University.

Sungsik
(Sung) Lee has been our President since our inception. Mr. Lee brings extensive experience in investment banking, venture capital,
and corporate development, with a proven track record of sourcing and executing M&A, strategic investment, and financing transactions.
Most recently, Mr. Lee led cross-border M&A and strategic investments across the broad sustainability-focused areas at the Global
Development Group of SK, the third-largest conglomerate in Korea with more than 100 affiliates over diverse sectors including energy,
ICT, and life sciences. Prior to SK, Mr. Lee was at SunTrust Robinson Humphrey, where he advised many publicly traded industrial companies
on M&A and capital market transactions. Before joining SunTrust, Mr. Lee was at Progress Partners, a media and technology-focused
investment banking firm, where he executed M&A and financing projects for early-to-mid-stage clients and managed three investment
funds at Progress Ventures, its affiliated venture capital arm. Mr. Lee received his B.A. from Hanyang University and M.B.A. from Cornell
University.

Dr.
Gene Young Cho has been our Chief Operating Officer since our inception. Dr. Gene Young Cho brings leadership and experience
in business operations and life sciences. Currently, he is the Executive Director of CG Pharmaceuticals, Inc., the U.S. subsidiary of
CrystalGenomics. In this role, Dr. Cho is focused on developing growth strategies as well as providing strategic planning and management
of the operations and expansion of CG Pharmaceuticals. Previously, Dr. Cho worked as a life sciences consultant at L.E.K. Consulting,
working with clients in biopharmaceuticals, contract services, medical devices, healthcare services, HCIT, digital health, and AI. Some
of his specific experiences include working on large-scale M&A transactions of leading biopharmaceuticals or healthcare service companies,
supporting target identification for acquisition, implementing pipeline development strategies, and optimizing governance structures
of fast-growing biotech companies. He also brings strong experience in the Asian markets through his professional network focused around
supporting emerging technologies and startups. Dr. Cho received his B.S. in bioengineering at U.C. Berkeley, Ph.D